ArticleBiotechnologia2026
Synergistic and dose-dependent pharmacological effects of black shallot and nano-curcumin combination on nociceptive, pyretic, and inflammatory responses in murine models.
Article in Biotechnologia, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Inflammation, pain, and fever are common features of chronic diseases and are often inadequately controlled by existing therapies. This study evaluated a fixed-ratio combination of black shallot extract and nano-curcumin (EBSC) for dose-dependent and synergistic antinociceptive, antipyretic, and anti-inflammatory effects in murine models. Materials and methods: EBSC (100, 200, and 300 mg/kg; oral) was assessed in Swiss albino mice using the hot-plate and tail-flick tests (antinociception), Brewer's yeast-induced pyrexia (antipyretic), and carrageenan-induced paw edema (anti-inflammatory). TRPV1, COX-2, PGE Results: EBSC produced dose-dependent analgesic effects: hot-plate reaction latency increased from 37.92 ± 1.24 s (100 mg/kg) to 40.05 ± 1.89 s (300 mg/kg), and pain inhibition increased to 62.48 ± 1.73% ( Conclusions: EBSC exhibits dose-dependent and synergistic antinociceptive, antipyretic, and anti-inflammatory activities with a favorable acute safety profile, supporting its potential for further development as a standardized phytopharmaceutical.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.